KMT2A and acute myeloid leukemia: Studies have shown that elevated expression of FTO occurs in a specific subset of cases such as with t (11q23)/MLL rearrangements, t (15;17)/PML::RARA, FLT3-ITD and/or NPM1 mutations [19], and t (8;21) AML [32].